Loading…
for educational and safety purposes
Deschloroketamine and 2-Fluorodeschloroketamine both come up in the same conversations; they overlap on Glutamate and Pain. Deschloroketamine: Deschloroketamine (DCK) is an arylcyclohexylamine dissociative and a ketamine analogue in which the aromatic chlorine of ketamine is removed. 2-Fluorodeschloroketamine: 2-Fluorodeschloroketamine (2-FDCK, 2F-DCK) is an arylcyclohexylamine dissociative and a fluorinated analog of ketamine in which the aromatic chlorine is replaced by fluorine, and it is presumed to share ketamine's mechanism as an N-methyl-D-aspartate (NMDA) receptor antagonist.
Deschloroketamine (DCK) is an arylcyclohexylamine dissociative and a ketamine analogue in which the aromatic chlorine of ketamine is removed. Like ketamine and related arylcyclohexylamines, it is presumed to act principally as an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor, producing dissociative and anaesthetic-like effects, and users report a comparatively longer duration than ketamine. It emerged on the new psychoactive substance market alongside the fluorinated analogue 2-fluorodeschloroketamine (2F-DCK), of which DCK is also a metabolite, and forensic studies have mapped its extensive hepatic metabolism and urinary and hair biomarkers. Addictovigilance and toxicology reports associate DCK and its congeners with dissociation, impaired consciousness, redosing, and serious outcomes including fatalities, and chronic heavy use carries the urinary and bladder toxicity concerns characteristic of the ketamine class.
2-Fluorodeschloroketamine (2-FDCK, 2F-DCK) is an arylcyclohexylamine dissociative and a fluorinated analog of ketamine in which the aromatic chlorine is replaced by fluorine, and it is presumed to share ketamine's mechanism as an N-methyl-D-aspartate (NMDA) receptor antagonist. It has circulated widely as an inexpensive research chemical producing a broadly ketamine-like dissociative state, and its extensive metabolism has been mapped in human liver microsomes, urine, and hair, with nor-2F-DCK identified as a principal metabolite. Addictovigilance surveillance has linked ketamine analogues including 2-FDCK to serious neurological and psychiatric events and to recorded deaths, and case reports describe emergency presentations in a dissociated state after insufflation. Like other arylcyclohexylamines, it carries risks of compulsive redosing and, with chronic use, urinary tract and bladder toxicity.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
Antagonist
Antagonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.